Edition:
United States

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

2.09USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$2.09
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,554
52-wk High
$2.95
52-wk Low
$1.80

Select another date:

Mon, Dec 11 2017

BRIEF-Sophiris Bio Announces Complete Enrollment In Phase 2B Topsalysin Study

* SOPHIRIS BIO ANNOUNCES COMPLETE ENROLLMENT IN PHASE 2B TOPSALYSIN STUDY OF LOCALIZED PROSTATE CANCER Source text for Eikon: Further company coverage:

BRIEF-Sophiris Bio posts Q3 loss per share $0.09

* Sophiris Bio reports third quarter financial results and key corporate highlights

BRIEF-bluebird bio reports qtrly ‍loss per share $1.73​

* bluebird bio reports third quarter 2017 financial results and recent operational progress

BRIEF-SOPHIRIS BIO PROVIDES ENROLLMENT UPDATE ON TOPSALYSIN PHASE 2B STUDY

* SOPHIRIS BIO PROVIDES ENROLLMENT UPDATE ON TOPSALYSIN PHASE 2B STUDY IN LOCALIZED PROSTATE CANCER

BRIEF-SOPHIRIS BIO ENTERED INTO LOAN AND SECURITY AGREEMENT OF UP TO $10 MLN IN TWO TERM LOANS​

* SOPHIRIS BIO- ‍ANNOUNCED THAT IT ENTERED INTO A LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK AND MAY BORROW UP TO $10 MILLION IN TWO TERM LOANS​ Source text for Eikon: Further company coverage:

BRIEF-Bluebird Bio Inc initiates ‍expansion cohort of CRB-401 Phase 1 study of bb2121

* bluebird bio Inc - ‍expansion cohort of crb-401 phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated​

Select another date: